Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "Results From the MEDISARC Phase II Study of Durvalumab & Tremelimumab Compared to Doxorubicin in Patients With Advanced/Metastatic Soft Tissue Sarcoma"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Viktor Grünwald
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Viktor Grünwald
Comments 0
Login to view comments.
Click here to Login
